US Stock MarketDetailed Quotes
RCUS Arcus Biosciences
- 14.700
- +0.420+2.94%
Close Nov 22 16:00 ET
1.35BMarket Cap-4608P/E (TTM)
15.070High14.200Low534.48KVolume14.290Open14.280Pre Close7.92MTurnover1.04%Turnover RatioLossP/E (Static)91.51MShares20.31052wk High2.38P/B756.75MFloat Cap13.49552wk Low--Dividend TTM51.48MShs Float49.100Historical High--Div YieldTTM6.09%Amplitude6.300Historical Low14.813Avg Price1Lot Size
Arcus Biosciences Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 141.27%26M | -64.91%-94M | 97.96%-2M | -169.86%-306M | -25.71%-88M | 22.22%-63M | 12.31%-57M | -114.98%-98M | 271.09%438M | -13.03%-70M |
| Net income from continuing operations | -29.58%-92M | -24.00%-93M | 95.00%-4M | -14.98%-307M | -20.90%-81M | -9.23%-71M | -11.94%-75M | -17.65%-80M | -603.77%-267M | -123.97%-67M |
| Depreciation and amortization | 100.00%2M | 0.00%2M | 50.00%3M | 33.33%8M | 200.00%3M | -50.00%1M | 0.00%2M | 100.00%2M | 50.00%6M | -29.43%1M |
| Other non cash items | -33.33%2M | 50.00%3M | -33.33%2M | -9.09%10M | 0.00%2M | 200.00%3M | -33.33%2M | -40.00%3M | 266.67%11M | 53.96%2M |
| Change In working capital | 1,222.22%101M | ---19M | 2.63%-37M | -111.40%-71M | -14.29%-24M | 74.29%-9M | --0 | -105.45%-38M | 265.69%623M | 94.18%-21M |
| -Change in receivables | 9.09%12M | 450.00%7M | 116.67%13M | -97.87%15M | --0 | 57.14%11M | 66.67%-2M | -99.16%6M | 4,241.18%704M | 30.14%-12M |
| -Change in payables and accrued expense | -116.67%-1M | --0 | -110.00%-1M | -112.50%-1M | -75.00%2M | 150.00%6M | -575.00%-19M | 25.00%10M | 260.00%8M | 133.58%8M |
| -Change in other current assets | 109.09%1M | 42.86%10M | 162.50%5M | -800.00%-14M | -133.33%-2M | -57.14%-11M | -30.00%7M | -14.29%-8M | 166.67%2M | 260.00%6M |
| -Change in other current liabilities | 29.41%22M | -62.50%3M | 42.86%-12M | -114.29%-3M | -163.64%-7M | 70.00%17M | 700.00%8M | -2,000.00%-21M | 23.53%21M | -40.24%11M |
| -Change in other working capital | 309.38%67M | -750.00%-39M | -68.00%-42M | 39.29%-68M | 50.00%-17M | 3.03%-32M | 122.22%6M | -38.89%-25M | 69.57%-112M | 89.99%-34M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 141.27%26M | -64.91%-94M | 97.96%-2M | -169.86%-306M | -25.71%-88M | 22.22%-63M | 12.31%-57M | -114.98%-98M | 271.09%438M | -13.03%-70M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -363.64%-29M | 142.31%63M | -231.01%-169M | 146.97%194M | -40.43%28M | -52.17%11M | 112.09%26M | 148.13%129M | -10,225.00%-413M | 150.24%47M |
| Net PPE purchase and sale | 90.00%-1M | --0 | -33.33%-4M | -300.00%-24M | ---6M | -400.00%-10M | -400.00%-5M | 0.00%-3M | 76.92%-6M | --0 |
| Net intangibles purchase and sale | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---3M | --0 |
| Net investment purchase and sale | -233.33%-28M | 103.23%63M | -225.00%-165M | 153.96%218M | -27.66%34M | -4.55%21M | 114.90%31M | 149.81%132M | -1,936.36%-404M | 72.73%47M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -363.64%-29M | 142.31%63M | -231.01%-169M | 146.97%194M | -40.43%28M | -52.17%11M | 112.09%26M | 148.13%129M | -10,225.00%-413M | 150.24%47M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 700.00%48M | -91.30%2M | 22,800.00%229M | 0.00%33M | -72.73%3M | 100.00%6M | 475.00%23M | -93.33%1M | -86.08%33M | -2.92%11M |
| Net common stock issuance | --0 | --0 | --228M | --25M | --0 | --5M | --20M | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | 100.00%2M | 0.00%3M | 0.00%1M | -65.22%8M | -50.00%3M | -66.67%1M | -25.00%3M | -90.00%1M | 91.67%23M | -8.54%6M |
| Net other financing activities | ---1M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 100.00%10M | --5M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 700.00%48M | -91.30%2M | 22,800.00%229M | 0.00%33M | -72.73%3M | 100.00%6M | 475.00%23M | -93.33%1M | -86.08%33M | -2.92%11M |
| Net cash flow | ||||||||||
| Beginning cash position | -31.76%159M | -21.99%188M | -37.80%130M | 38.41%209M | -15.38%187M | -15.58%233M | -56.34%241M | 38.41%209M | -13.22%151M | 21.14%221M |
| Current changes in cash | 197.83%45M | -262.50%-29M | 81.25%58M | -236.21%-79M | -375.00%-57M | 16.36%-46M | 97.10%-8M | -92.02%32M | 352.17%58M | 62.29%-12M |
| End cash Position | 9.09%204M | -31.76%159M | -21.99%188M | -37.80%130M | -37.80%130M | -15.38%187M | -15.58%233M | -56.34%241M | 38.41%209M | 38.41%209M |
| Free cash flow | 134.25%25M | -51.61%-94M | 94.06%-6M | -177.46%-330M | -34.29%-94M | 12.05%-73M | 13.89%-62M | -115.51%-101M | 251.06%426M | 0.51%-70M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data